Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 18:15:1480186.
doi: 10.3389/fphar.2024.1480186. eCollection 2024.

Comparison of sGC activator and sGC stimulator in 5/6 nephrectomized rats on high-salt-diet

Affiliations

Comparison of sGC activator and sGC stimulator in 5/6 nephrectomized rats on high-salt-diet

Xin Chen et al. Front Pharmacol. .

Abstract

Introduction: Soluble guanylate cyclase (sGC) stimulators and activators are known to enhance kidney function in various models of chronic kidney disease (CKD) by increasing cyclic guanosine monophosphate (cGMP). Their differential effects on CKD progression, particularly under conditions of oxidative stress, remain unexplored by direct comparative studies.

Methods: We conducted a side-by-side comparison using 5/6 nephrectomized rats on a high salt diet (5/6Nx+HSD) to evaluate the efficacy of the sGC stimulator BAY 41-8543 and the sGC activator BAY 60-2770 in CKD progression. BAY 41-8543 (1 mg/kg; twice daily) and BAY 60-2770 (1 mg/kg; once daily) were administered by gavage for 11 weeks.

Results: The 5/6Nx+HSD model led to increased plasma creatinine, proteinuria, and blood pressure. Both BAY 41-8543 and BAY 60-2770 significantly reduced systolic and diastolic blood pressure to a similar extent but did not improve renal function parameters. Notably, BAY 60-2770 reduced renal fibrosis, including interstitial fibrosis and glomerulosclerosis, whereas BAY 41-8543 did not. These antifibrotic effects of BAY 60-2770 were independent of blood pressure reduction. Proteomic analysis revealed that BAY 60-2770 corrected the upregulation of 9 proteins associated with apoptosis and fibrosis, including Caspase-3, MKK6 (Mitogen-Activated Protein Kinase Kinase 6), Prdx5 (Peroxiredoxin-5), in the 5/6Nx+HSD group.

Discussion: In contrast, BAY 41-8543 had no significant impact on these proteins. sGC activators were more effective than sGC stimulators in reducing renal fibrosis in 5/6 nephrectomized rats on a high salt diet, and this effect was due to modulation of apoptosis-associated proteins beyond the control of blood pressure.

Keywords: apoptosis; chronic kidney disease; renal fibrosis; soluble guanylate cyclase activator; soluble guanylate cyclase stimulator.

PubMed Disclaimer

Conflict of interest statement

Authors DD and TK were employed by Boehringer Ingelheim Pharma GmbH & Co. KG. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Time course of the animal study. SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; HSD: High Salt Diet; MC: Metabolic Cages; Poles amputation: Amputation of both poles of left kidney; Uni-Nx: Unilateral nephrectomy of the right kidney.
FIGURE 2
FIGURE 2
Kidney morphology. (A) Photomicrographs of sirius red-stained kidneys for the detection of fibrosis, scale bar = 100 μm. (B) Photomicrographs of periodic acid Schiff-stained kidneys for the detection of glomerulosclerosis and glomerular size, scale bar = 50 μm. (C) Photomicrographs of collagen I immunostaining, the red color indicates the area of collagen deposition, scale bar = 100 μm. (D) Renal interstitial fibrosis. (E) Glomerulosclerosis index. (F) Glomerular size. (G) Immunofluorescence analysis of renal collagen I. Sham: Sham operation; 5/6Nx: 5/6 nephrectomy model; PBO: Placebo; ND: Normal Diet; HSD: High Salt Diet. *p< 0.05; **p< 0.01; ***p< 0.001; ****p< 0.0001, significantly different from 5/6Nx + HSD + PBO.

References

    1. Almazroue H., Jin Y., Nelin L. D., Barba J. C., 2nd, Milton A. D., Trittmann J. K. (2023). Human pulmonary microvascular endothelial cell DDAH1-mediated nitric oxide production promotes pulmonary smooth muscle cell apoptosis in co-culture. Am. J. Physiol. Lung Cell Mol. Physiol. 325 (3), L360–L367. 10.1152/ajplung.00433.2021 - DOI - PMC - PubMed
    1. Bai Y., Ye S., Mortazavi R., Campese V., Vaziri N. D. (2007). Effect of renal injury-induced neurogenic hypertension on NO synthase, caveolin-1, AKt, calmodulin and soluble guanylate cyclase expressions in the kidney. Am. J. Physiol. Ren. Physiol. 292 (3), F974–F980. 10.1152/ajprenal.00157.2006 - DOI - PubMed
    1. Balzer M. S., Pavkovic M., Frederick J., Abedini A., Freyberger A., Vienenkotter J., et al. (2023). Treatment effects of soluble guanylate cyclase modulation on diabetic kidney disease at single-cell resolution. Cell Rep. Med. 4 (4), 100992. 10.1016/j.xcrm.2023.100992 - DOI - PMC - PubMed
    1. Bulow R. D., Boor P. (2019). Extracellular matrix in kidney fibrosis: more than just a scaffold. J. Histochem Cytochem 67 (9), 643–661. 10.1369/0022155419849388 - DOI - PMC - PubMed
    1. Cui W., Maimaitiyiming H., Qi X., Norman H., Zhou Q., Wang X., et al. (2014). Increasing cGMP-dependent protein kinase activity attenuates unilateral ureteral obstruction-induced renal fibrosis. Am. J. Physiol. Ren. Physiol. 306 (9), F996–F1007. 10.1152/ajprenal.00657.2013 - DOI - PMC - PubMed

LinkOut - more resources